WO2010114185A1 - 암 특이 면역반응 유도능을 갖는 수지상 세포의 제조 방법, 이 수지상 세포를 포함하는 암의 예방, 치료, 또는 전이 억제용 약제학적 조성물 및 키트 - Google Patents

암 특이 면역반응 유도능을 갖는 수지상 세포의 제조 방법, 이 수지상 세포를 포함하는 암의 예방, 치료, 또는 전이 억제용 약제학적 조성물 및 키트 Download PDF

Info

Publication number
WO2010114185A1
WO2010114185A1 PCT/KR2009/001650 KR2009001650W WO2010114185A1 WO 2010114185 A1 WO2010114185 A1 WO 2010114185A1 KR 2009001650 W KR2009001650 W KR 2009001650W WO 2010114185 A1 WO2010114185 A1 WO 2010114185A1
Authority
WO
WIPO (PCT)
Prior art keywords
dendritic cells
cancer
preventing
mature dendritic
immune response
Prior art date
Application number
PCT/KR2009/001650
Other languages
English (en)
French (fr)
Inventor
배용수
민미경
성영림
장진아
윤선옥
Original Assignee
주식회사 중외제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 중외제약 filed Critical 주식회사 중외제약
Priority to PCT/KR2009/001650 priority Critical patent/WO2010114185A1/ko
Priority to CN2009801585170A priority patent/CN102439137A/zh
Publication of WO2010114185A1 publication Critical patent/WO2010114185A1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 암 특이면역반응 유도능력이 현저히 향상된 성숙 수지상세포의 제조방법, 상기 방법에 의해 제조된 성숙 수지상세포를 포함하는 암의 예방, 치료 또는 전이 억제용 약제학적 조성물 및 상기 방법에 의해 제조된 성숙 수지상세포와 이미퀴모드를 포함하는 약제학적 키트에 관한 것이다. 본 발명의 방법에 의하면 암 특이면역반응 유도능력이 현저히 향상되고, 독성이 매우 적은 안전한 성숙 수지상세포를 제조할 수 있다. 본 발명의 방법에 의해 제조된 성숙 수지상세포는 암의 치료, 예방 및 전이억제 효과가 매우 뛰어나다. 본 발명의 약제학적 키트에 사용되는 이미퀴모드는 암특이적 성숙 수지상세포 투여에 의한 암의 면역 치료, 예방 효능 및 암 전이 억제 효능을 놀라울 정도로 향상시킨다.
PCT/KR2009/001650 2009-03-31 2009-03-31 암 특이 면역반응 유도능을 갖는 수지상 세포의 제조 방법, 이 수지상 세포를 포함하는 암의 예방, 치료, 또는 전이 억제용 약제학적 조성물 및 키트 WO2010114185A1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/KR2009/001650 WO2010114185A1 (ko) 2009-03-31 2009-03-31 암 특이 면역반응 유도능을 갖는 수지상 세포의 제조 방법, 이 수지상 세포를 포함하는 암의 예방, 치료, 또는 전이 억제용 약제학적 조성물 및 키트
CN2009801585170A CN102439137A (zh) 2009-03-31 2009-03-31 具有诱导癌症特异性免疫反应的能力的树突状细胞的制备方法,包含该树突状细胞的用于预防或治疗癌症或者抑制癌症转移的药物组合物及试剂盒(kit)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2009/001650 WO2010114185A1 (ko) 2009-03-31 2009-03-31 암 특이 면역반응 유도능을 갖는 수지상 세포의 제조 방법, 이 수지상 세포를 포함하는 암의 예방, 치료, 또는 전이 억제용 약제학적 조성물 및 키트

Publications (1)

Publication Number Publication Date
WO2010114185A1 true WO2010114185A1 (ko) 2010-10-07

Family

ID=42828463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001650 WO2010114185A1 (ko) 2009-03-31 2009-03-31 암 특이 면역반응 유도능을 갖는 수지상 세포의 제조 방법, 이 수지상 세포를 포함하는 암의 예방, 치료, 또는 전이 억제용 약제학적 조성물 및 키트

Country Status (2)

Country Link
CN (1) CN102439137A (ko)
WO (1) WO2010114185A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149871A1 (en) * 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
KR101518972B1 (ko) * 2014-08-01 2015-05-18 제이더블유크레아젠 주식회사 수지상세포의 제조방법, 이에 의해 제조된 수지상세포 및 그 용도
WO2018119610A1 (zh) * 2016-12-26 2018-07-05 广州中科蓝华生物科技有限公司 一种重组质粒、其构建的重组疟原虫及其应用
WO2019144047A1 (en) * 2018-01-18 2019-07-25 University Of South Florida Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases
CN110922492B (zh) * 2019-12-18 2022-02-15 重庆医科大学 融合肽、ctp介导的诱导cml细胞免疫应答的dc疫苗及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077289A1 (en) * 2001-02-15 2003-04-24 Rong-Fu Wang Use of cell-penetrating peptides to generate antitumor immunity
US20050154188A1 (en) * 2002-03-29 2005-07-14 Dae-You Kim Cytoplasmic tranduction peptides and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077289A1 (en) * 2001-02-15 2003-04-24 Rong-Fu Wang Use of cell-penetrating peptides to generate antitumor immunity
US20050154188A1 (en) * 2002-03-29 2005-07-14 Dae-You Kim Cytoplasmic tranduction peptides and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BATCHU, R.B. ET AL.: "Protein Transduction of Dendritic Cells for NY-ESO-1-Based Immunotherapy of Myeloma.'", CANCER RES., vol. 65, no. 21, 2005, pages 10041 - 10049 *
KUEBLER, H.R. ET AL.: "In situ Activation of Dendritic Cells with Imiquimod for Cancer Immunotherapy", PROC. AMER. ASSOC. CANCER RES., vol. 47, 2006 *
MAJEWSKI, S. ET AL.: "Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis.", INT'L J. DERMATOL., vol. 44, pages 14 - 19 *

Also Published As

Publication number Publication date
CN102439137A (zh) 2012-05-02

Similar Documents

Publication Publication Date Title
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
NZ706739A (en) Substituted benzene compounds
MX2015007921A (es) Compuestos heterociclicos novedosos como inhibidores de bromodominio.
JO3187B1 (ar) (4-(8- ميثوكسي بروبان -2-يل)-2-(تترا هيدرو - 2h - بيران-4-يل)- 1h - ايميدازو [ 4, 5- c ] كوينولين -7-يل)-3, 5- داي ميثيل ايزوكسازول واستخدامه كمثبط نطاق برومو
PH12014501835A1 (en) Novel adjuvant compositions
WO2014080290A3 (en) Cyclic amines as bromodomain inhibitors
CA2759013C (en) Combination immunotherapy compositions against cancer and methods
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
IN2012DN00446A (ko)
UA115983C2 (uk) Інгібітори днк-пк
UA111386C2 (uk) Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
MX349004B (es) Nuevos compuestos.
SG10201810928SA (en) Novel antitumoral use of cabazitaxel
IN2014DN10390A (ko)
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
MX2012001306A (es) Inhibicion de matastasis de tumor.
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
WO2010114185A1 (ko) 암 특이 면역반응 유도능을 갖는 수지상 세포의 제조 방법, 이 수지상 세포를 포함하는 암의 예방, 치료, 또는 전이 억제용 약제학적 조성물 및 키트
WO2015032800A3 (en) Compositions and methods for inducing senescence in cancer cells
SG194753A1 (en) Induction of il-12 using immunotherapy
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
IN2012DN01878A (ko)
WO2011006084A3 (en) Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980158517.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09842722

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 6566/CHENP/2011

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09842722

Country of ref document: EP

Kind code of ref document: A1